RU96120183A - PROGESTERON ANTAGONISTS FOR THE PRODUCTION OF MEDICINES IN THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING - Google Patents

PROGESTERON ANTAGONISTS FOR THE PRODUCTION OF MEDICINES IN THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING

Info

Publication number
RU96120183A
RU96120183A RU96120183/14A RU96120183A RU96120183A RU 96120183 A RU96120183 A RU 96120183A RU 96120183/14 A RU96120183/14 A RU 96120183/14A RU 96120183 A RU96120183 A RU 96120183A RU 96120183 A RU96120183 A RU 96120183A
Authority
RU
Russia
Prior art keywords
hydroxy
treatment
estradien
dimethylamino
phenyl
Prior art date
Application number
RU96120183/14A
Other languages
Russian (ru)
Other versions
RU2170580C2 (en
Inventor
Хвалиш Кристоф
Штекеманн Клаус
Original Assignee
Шеринг Аг
Filing date
Publication date
Application filed by Шеринг Аг filed Critical Шеринг Аг
Priority to RU96120183/14A priority Critical patent/RU2170580C2/en
Priority claimed from RU96120183/14A external-priority patent/RU2170580C2/en
Publication of RU96120183A publication Critical patent/RU96120183A/en
Application granted granted Critical
Publication of RU2170580C2 publication Critical patent/RU2170580C2/en

Links

Claims (8)

1. Применение конкурентного антагониста прогестерона (РА) для получения лекарственных средств для лечения дисфункциональных маточных кровотечений.1. The use of a competitive progesterone antagonist (RA) to obtain drugs for the treatment of dysfunctional uterine bleeding. 2. Применение РА по п.1 для получения лекарственных средств при лечении метрорагий. 2. The use of RA according to claim 1 for the manufacture of drugs in the treatment of metroragias. 3. Применение РА по п.1 для получения лекарственных средств при лечении менорагий. 3. The use of RA according to claim 1 for the manufacture of drugs in the treatment of menorrhagia. 4. Применение РА по п. 1 для изготовления лекарственных средств при лечении гиперменореи. 4. The use of RA according to claim 1 for the manufacture of medicines in the treatment of hypermenorrhea. 5. Применение конкурентного антагониста прогестерона по п.1, представляющего собой:
11β-//4-N, N-диметиламино/фенил/-17β-гидрокси-17α-пропинил-4,9/10/-эстрадиен-3-on /RU 38486/,
11β-//4-N, N-диметиламино/-фенил/-17β-гидрокси-18метил-17α-пропинил-4,9/10/-эстрадиен-3-on,
11β-//4-N,N-диметиламино/-фенил/-17 a β-гидрокси-17a α-пропинил-D-гомо-4,9/10/-эстрадиен-3-on,
11β-p-метоксифенил-17β-гидрокси-17 α-этил-4,9/10/-эстрадиен-3-on,
11β-/4-ацетилфенил/-17β-гидрокси-17α-/проп-1-инил/-4,9/10/-эстрадиен-3-on,
11β-/4-диметиламинофенил/-17α-гидрокси-17β-/3- гидроксипропил/-13 α-метил-4,9-гонадиент-3-on,
/Z/-11β-[4-диметиламино/фенил] -17β-гидрокси-17α-/3-гидрокси-1- пропенил/-эстр-4-en-3-on 5,
/Z/-11β-/4-диметиламино/фенил/-17β-гидрокси-17α-/3-гидрокси-1-пропенил/-эстр.-4-en-3-on 5,
11β, 19 -/4-ацетилфенил/-17β-гидрокси-17α-3-гидроксипроп-1-/Z/-енил/-4,9/10/-эстрадиен-3-on,
11β, 19 -/4-Цианфенил/-17β-гидрокси-17α-/3-гидроксипроп-1-/Z/-енил/-4-андростен-3-on или
11β,19-/4-/3-пиридинил/-о-фенилен/-17β-гидрокси-17α-/3-гидроксипроп-1-/Z/-енил/-4-андростен-3-on.5. The use of a competitive progesterone antagonist according to claim 1, which is:
11β - // 4-N, N-dimethylamino / phenyl / -17β-hydroxy-17α-propynyl-4.9 / 10 / -estradien-3-on / RU 38486 /,
11β - // 4-N, N-dimethylamino / phenyl / -17β-hydroxy-18methyl-17α-propynyl-4.9 / 10 / -estradien-3-on,
11β - // 4-N, N-dimethylamino / phenyl / -17 a β-hydroxy-17a α-propynyl-D-homo-4,9 / 10 / -estradien-3-on,
11β-p-methoxyphenyl-17β-hydroxy-17 α-ethyl-4,9 / 10 / -estradien-3-on,
11β- / 4-acetylphenyl / -17β-hydroxy-17α- / prop-1-ynyl / -4.9 / 10 / -estradien-3-on,
11β- / 4-dimethylaminophenyl / -17α-hydroxy-17β- / 3- hydroxypropyl / -13 α-methyl-4,9-gonadient-3-on,
/ Z / -11β- [4-dimethylamino / phenyl] -17β-hydroxy-17α- / 3-hydroxy-1-propenyl / -estr-4-en-3-on 5,
/ Z/-11β-/4- dimethylamino/phenyl/-17β- hydroxy-17α-/3- hydroxy-1- propenyl/-estr. 4-en-3-on 5,
11β, 19 - / 4-acetylphenyl / -17β-hydroxy-17α-3-hydroxyprop-1- / Z / -enyl / -4.9 / 10 / -estradien-3-on,
11β, 19 - / 4-Cyanophenyl / -17β-hydroxy-17α- / 3-hydroxyprop-1- / Z / -enyl / -4-androsten-3-on or
11β, 19- / 4- / 3-pyridinyl / -o-phenylene / -17β-hydroxy-17α- / 3-hydroxyprop-1- / Z / enyl / -4-androsten-3-on. 6. Применение РА по п.1 в ежедневной единице дозирования от 1 до 600 мг получения лекарственного средства при лечении дисфункциональных маточных кровотечений. 6. The use of RA according to claim 1 in a daily dosage unit of 1 to 600 mg of a drug in the treatment of dysfunctional uterine bleeding. 7. Применение РА по пп.1,6 в количестве от 50 до 400 мг. 7. The use of RA according to claims 1.6 in an amount of from 50 to 400 mg. 8. Применение 11 β-[4-диметиламинофенил]-17α-гидрокси-17β-/3-гидрокси-пропил/-13α-метил-4,9-гонадиен-3-она или от 50 до 400 мг /Z/-11β- -[4-(диметиламино)фенил]-17β-гидрокси-17α-/3-гидрокси-1-пропенил/-эстр-4-en-3-она по пп. 1,6 и 7 в количестве от 50 до 400 мг. 8. The use of 11 β- [4-dimethylaminophenyl] -17α-hydroxy-17β- / 3-hydroxy-propyl / -13α-methyl-4,9-gonadiene-3-one or from 50 to 400 mg / Z / -11β - - [4- (dimethylamino) phenyl] -17β-hydroxy-17α- / 3-hydroxy-1-propenyl / -estr-4-en-3-one according to claims 1.6 and 7 in an amount of 50 to 400 mg.
RU96120183/14A 1995-02-02 1995-02-02 Progesterone antagonists for preparing drugs used in treatment of patients with disfunctional uterine bleeding RU2170580C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU96120183/14A RU2170580C2 (en) 1995-02-02 1995-02-02 Progesterone antagonists for preparing drugs used in treatment of patients with disfunctional uterine bleeding

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU96120183/14A RU2170580C2 (en) 1995-02-02 1995-02-02 Progesterone antagonists for preparing drugs used in treatment of patients with disfunctional uterine bleeding

Publications (2)

Publication Number Publication Date
RU96120183A true RU96120183A (en) 1999-02-10
RU2170580C2 RU2170580C2 (en) 2001-07-20

Family

ID=20186377

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96120183/14A RU2170580C2 (en) 1995-02-02 1995-02-02 Progesterone antagonists for preparing drugs used in treatment of patients with disfunctional uterine bleeding

Country Status (1)

Country Link
RU (1) RU2170580C2 (en)

Similar Documents

Publication Publication Date Title
KR970704451A (en) Progesterone Antagonists Useful for Preparing Medicaments for Treating Dysfunctional Uterine Bleeding
RU2005124363A (en) SOLID ORAL DOSAGE FORMS OF VALSARTAN
DE69532927T2 (en) CYCLOPHASIC HORMONIC PROCEDURE CONTAINING ANTIPROGESTIN AND PROGESTINE
RU97106339A (en) METHOD FOR OBTAINING DOSING UNITS BY WET GRANULATION
KR970704450A (en) Use of a progesterone antagonist and gestagen to treat endometrial hyperplasia or uterine leiomyoma (Use of a Progesterone Antagonist and a Gestagen for Endometriosis or Leiomyomate Uteri)
US3639600A (en) Process of establishing cyclicity in a human female
HU224818B1 (en) The use of progestogen and estrogen for manufacturing a pharmaceutical composition for substitution therapy and oral contraception
CY1104981T1 (en) USE OF ANTI-PROGESTONES FOR THE PREVENTION AND TREATMENT OF HORMONE DEPENDENT DISEASES
RU2004130430A (en) 5- {2-HYDROXY-3- [1- (3-TRIFLUOROMETHYLPHENYL) CYCLOPROPYL] PROPIONYLAMINO} -PHTHALIDE AND RELATED COMPOUNDS HAVING MODULATING ACTIVITY AGAINST AREA RESEARCH
ES2348038T5 (en) Polyphasic preparation for contraception based on a natural estrogen
JP2005516913A5 (en)
RU2002121546A (en) SUBSTANCES FOR THE TREATMENT OF PSORIASIS
KR100450649B1 (en) Novel hormonal medicaments and use thereof for correcting oestrogen deficiencies
SK285056B6 (en) Use of estroprogestative hormonal composition
RU96120183A (en) PROGESTERON ANTAGONISTS FOR THE PRODUCTION OF MEDICINES IN THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING
JP2003048836A (en) Low-dose oral contraceptive with sustained efficacy that induces amenorrhea
RU2006145077A (en) APPLICATION OF COMBINATION OF ETHINYLESTRADIOL AND CHLORMADINONE ACETATE FOR PREPARING A MEDICINAL PRODUCT
NL8202773A (en) APAP ANTI-ACID COMPOSITION.
WO1998006404A1 (en) Combinations for hormone replacement therapy containing a natural oestrogen, a natural progestogen and a natural androgen
JP2582088B2 (en) Inhibitors of prostaglandin synthesis in the uterus
Greenblatt Perlingual Absorption of Progesterone and Anhydrohydroxyprogesterone, II. Clinical Evaluation
JPH0782169A (en) Wound healing agent
KR19990087672A (en) Sequential Estrogen / Progesterone Antagonist Formulation for Hormone Replacement Therapy
JP2716461B2 (en) Pharmaceutical containing progesterone synthesis inhibitor and antigestagen and method for producing the same
JP2001048805A (en) Therapeutic drug for treating and preventing osteoporosis, cardiovascular disease and chest cancer